NCT03131479View on ClinicalTrials.gov

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 28, 2017

Primary Completion Date

January 16, 2018

Study Completion Date

January 16, 2018

Conditions
Renal Impairment
Interventions
DRUG

LIK066

LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.

Trial Locations (1)

32809

Novartis Investigative Site, Orlando

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY